Fujifilm Diosynth Biotechnologies expands cell culture manufacturing capacity
Adds new 2,000L single-use bioreactors in the US and UK
Fujifilm Diosynth Biotechnologies has continued to expand its cell culture manufacturing capabilities with the addition of two 2000L single-use bioreactors. One is being installed at the company’s site in Research Triangle Park (RTP), NC, US and the other at Billingham, UK.
The new reactors will complement the vessels installed at both sites, adding further flexibility to meet customer requirements. Each site currently operates 1000L single-use bioreactors with 250L to 1,000L operating volumes, with an additional 200L single-use bioreactor in the UK, and a 2000L stainless steel train in RTP, which has been in place for a number of years manufacturing a range of products.
'The addition of these two new bioreactors will meet the demand we are seeing for a 2000L platform, and offer a cost-effective, low-risk route to market through ‘scaling-out’ from early phase to commercial manufacture,' says Steve Bagshaw, Chief Executive at Fujifilm Diosynth Biotechnologies.
He adds: 'Being similar to our existing bioreactors means they will fit seamlessly into our facilities. Having identical single-use operations on both sides of the Atlantic offers our customers flexibility and easy access to global markets. Combined with the expertise of our process development scientists to produce high-titer cell lines, our focus on single-use bioreactor technology for cell culture processes is world class.'
The company has more than 15 years’ cell culture manufacturing experience with significant single-use facility expansions in the last three years at both sites. The facilities have been inspected by key regulatory authorities and use traditional platforms as well as the latest single-use technologies. The new 2000L bioreactors are expected to be operational by November in the US and in the UK by January 2015.
